NRx Pharmaceuticals, Inc.
NRXP
$3.87
-$0.46-10.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.43M | 360.00K | -5.89M | -17.58M | -5.51M |
| Total Depreciation and Amortization | 165.00K | 100.00K | 43.00K | -- | 1.00K |
| Total Amortization of Deferred Charges | -- | 0.00 | 0.00 | 0.00 | 350.00K |
| Total Other Non-Cash Items | -3.36M | -5.53M | 2.39M | 14.07M | 1.68M |
| Change in Net Operating Assets | 331.00K | 1.36M | 567.00K | -516.00K | 0.00 |
| Cash from Operations | -4.30M | -3.71M | -2.89M | -4.03M | -3.48M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 183.00K | -2.56M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -213.00K | -432.00K | -- | -- | -- |
| Cash from Investing | -213.00K | -249.00K | -2.56M | -- | -- |
| Total Debt Issued | -- | 0.00 | -225.00K | 452.00K | -- |
| Total Debt Repaid | -- | -154.00K | 0.00 | -74.00K | -320.00K |
| Issuance of Common Stock | -- | 0.00 | 6.21M | 0.00 | 8.26M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.42M | 4.73M | 3.74M | 1.01M | -350.00K |
| Cash from Financing | 3.42M | 4.58M | 9.73M | 1.39M | 7.59M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.08M | 613.00K | 4.27M | -2.64M | 4.11M |